Scientific Posters & Practice Pearl Posters
Sunday, September 10
10:05-10:40 am
AMD/ANTI-ANGIOGENESIS
101	Correlation of Optical Coherence Tomography and Retinal Angiography in Patients Treated with Bevacizumab for CNV Membrane Swati Agarwal, MD
102	Macrophages inhibit neovascularization in a murine model of ARMD Rajendra S. Apte, MD, PhD
103	Triple Combination Therapy (PDT with Intravitreal Bevacizumab and Subtenon Triamcinolone Acetonide) for CNV Alay S. Banker, MD
104	Vision Improvement with Combination Low-Fluence Photodynamic Therapy (LFPDT) and Intravitreal Injection Gregory R. Blaha, MD, PhD
105	Survey of Current and Future Avastin Usage: Emphasis on Economics Gregory R. Blaha, MD, PhD
106	PDT for Subfoveal Predominantly Hemorrhagic CNV Lesion Secondary to ARMD Francesco Boscia, MD
107	Evaluation of Relationship between VEGF levels and ARMD K. V. Chalam, MD, PhD
108	Retinal Pigment Epithelial Tears after Intraocular Bevacizumab (Avastintm) Injection for Neovascular ARMD Clement K. Chan, MD
109	Use of Double Reciprocal Analysis to Compare Pharmacological Treatments for Subfoveal Exudative ARMD Lucian V. Del Priore, MD, PhD
110	Comparison of PDT Combined With Immediate Versus Delayed IVT Acetonide for CNV Ajay Dudani, MD
111	Age Influence on the Results of PDT of Subfoveal or Juxtafoveal CNV in Pathologic Myopia Leila El Matri, MD
112	Subretinal Surgery with the Combination RPE and Choroidal Transplantation for the Treatment of ARMD Related Visual Loss in a US Management Algorithm Calvin A. Grant, MD
113	Sequential Pegaptanib Monotherapy following Verteporfin PDT for CNV Paul B. Griggs, MD
114	Expression of VEGF and Endostatin in Human CNV Membranes following Verteporfin PDT Salvatore Grisanti, MD
115	Comparison between IVT and Bevacizumab for Serous PED and Occult CNV Secondary to ARMD David Hauser, MD
116	Combination Pegaptanib and PDT for Subfoveal CNV Secondary to ARMD ThucAnh Thi Ho, MD
117	VeriTAS: Study Design and Baseline Characteristics for a Combination Therapy Trial in Wet ARMD Peter K. Kaiser, MD
118	Combined PDT and IVT Injection for the Treatment of Subfoveal CNV Noha Khater
119	Clinical Characteristics of Exudative ARMD in Asian Patients Gregg T. Kokame, MD
120	Vascular Leakage as a Predictive Factor of Outcome of PDT with Visudyne® Jaco Lavinsky, MD
121	Outcomes of PDT for idiopathic Polypoidal Choroidal Vasculopathy Mun-Wai Lee, MD
122	Multifocal electroretinographic long-term follow up in 12 cases of minimally classic or occult SRNV in ARMD treated with Pegaptanib sodium (Macugen) Andreas Lipski, MD
123	Clinical course of massive submacular hemorrhage: a Hong Kong perspective David TL Liu, MD
124	New Progress in the Surgical Treatment of ARMD by Vortex Vein Occlusion Richard Luscan, MD
125	Visual Outcome of Intravitreal Bevacizumab for Neovascular ARMD Charles E. Lyon, MD
126	Combined Intravitreal Avastin with Phacoemulsification in Visually Significant Cataract and Visually Significant Maculopathy Ahmad M. Mansour, MD
127	Treatment of neovascular ARMD with Intravitreal Bevacizumab (Avastin®): efficacy of 3 consecutive monthly injections Alex Melamud, MD
128	Systemic Avastin Therapy for Neovascular ARMD Jose Luis Rosales Meneses, MD, PhD
129	Intravitreal Bevacizumab Therapy For Neovascular ARMD: A Pilot Study Virgilio Morales-Canton, MD
130	Agreement among Canadian Retina Specialists In The Determination Of Treatment Eligibility For PDT In ARMD Rajeev Hemant Muni, MD
131	The Role of Hyperthermia in Control of Sufoveal CNV: Stabilization of CNV With Low Recurrent Rate Masood Naseripour, MD
132	Novel Macular Photorecovery Timer Detected Early Wet ARMD Changes David A. Newsome, MD
133	Quality of Life in Patients with ARMD: Results from the V.I.S.I.O.N. Trial Manjula Patel, MD
134	The Relationship Between Cataract Surgery, ARMD and PDT Ayala Pollack, MD
135	Recurrence of CNV 18 months after PDT with or without Kenalog in ARMD Michael J. Potter, MD
136	Vision-Specific Quality of Life at 12 Months in Subjects with or without Classic CNV due to ARMD: Phase III Clinical Trial of Ranibizumab (Lucentis) Carl Regillo, MD
137	The Effect of Blue Light on Vascular Endothelial Growth Factor Kourous A. Rezai, MD
138	Thermal Laser Photocoagulation Combined with IVT Injection for Treatment of CNV Edwin H. Ryan, MD
139	Triple Therapy: PDT, Intravitreal Bevacizumab and Preservative Free Triamcinolone Acetonide for the Treatment of Exudative ARMD Arturo Santos, MD, PhD
140	Avastin Adjuvants in CNV Surgery Joerg C. Schmidt, MD
141	The PHP-II (Automated Preferential Hyperacuity Perimeter) For Detection of CNV in ARMD Ruth Axer Siegel, MD
142	Effect on High Contrast Discriminated Target Central Fields of PDT with Vertporphyrin for CNVM due to ARMD Stephen H. Sinclair, MD
143	Hypericin–Enhanced Argon Laser Photocoagulation for Subfoveal CNV Membrane in ARMD GŸngšr Sobaci, MD
144	Intravitreal combination of Kenacort and Avastin (Ken-Av) for CNV ARMD Panos Stergiou
145	The Relative Systemic Safety of Differing ARMD Therapies Ivan J Suner, MD
146	Expression of VEGF and PEDF in CNV Membranes following Verteporfin PDT Olcay Tatar, MD
147	Combination Therapy of PDT with Verteporfin and Intravitreal Pegaptanib in the Management of Exudative ARMD Asheesh Tewari, MD
148	Suspension Phase Microsphere Immunoassay of Bevacizumab Levels in Ocular Fluids and Sera Susan J Wong, PhD
149	Autologous Iris Pigment Epithelium Cell Transplantation for treatment of Dry MD: 2-year follow-up Narendra Armogan, MD, FRCS(C)
150	Avastin—It’s Not Just for Retina Anymore Michael A. Singer, MD
151	Treatment of Macular Hematoma due to ARMD by Displacement with Vitrectomy and Gas Injection Jean-François Le Rouic, MD
152	Tritherapy using Avastin, Visudyne and Triamcinolone as Treatment of Neovascular ARMD Guy L'Helgoual'ch